As filed with the Securities and Exchange Commission on January 12, 2023.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
Form S-8
REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OF 1933
MIROMATRIX MEDICAL INC. |
(Exact Name of Registrant as Specified in its Charter) |
Delaware | 27-1285782 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
6455 Flying Cloud Drive, Suite 107 Eden Prairie, MN | 55344 | |
(Address of Principal Executive Offices) | (Zip Code) |
Miromatrix Medical Inc. 2021 Equity Incentive Plan
Miromatrix Medical Inc. Employee Stock Purchase Plan
(Full Title of the Plan)
Jeffrey Ross Chief Executive Officer Miromatrix Medical Inc. 6455 Flying Cloud Drive, Suite 107 Eden Prairie, MN 55344 (Name and Address of Agent for Service)
|
Telephone number, including area code, of agent for service: (952) 942-6000
Copies to:
Steven C. Kennedy
Joshua L. Colburn
Faegre Drinker Biddle & Reath LLP
2200 Wells Fargo Center
90 South Seventh Street
Minneapolis, Minnesota 55402-3901
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer ¨ | Accelerated Filer ¨ |
Non-accelerated Filer þ | Smaller Reporting Company þ |
Emerging Growth Company þ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
MIROMATRIX MEDICAL INC.
STATEMENT PURSUANT TO GENERAL INSTRUCTION E
TO FORM S-8 “REGISTRATION OF ADDITIONAL SECURITIES”
The 2021 Equity Incentive Plan (the “2021 Plan”) of Miromatrix Medical Inc. (the “Company”) provides, among other things, that the number of shares of the Company’s common stock, $0.00001 par value per share (the “Common Stock”), reserved for issuance under the 2021 Equity Incentive Plan will be increased on January 1 of each year, commencing on January 1, 2022 and ending on (and including) January 1, 2031 in an amount equal to the least of: (i) 4.5% of the total number of shares of Common Stock outstanding as of December 31 of the immediately preceding calendar year; (ii) 600,000 shares of Common Stock; or (iii) such lesser number of shares of Common Stock as may be determined by the Company’s Board of Directors (the “Board”).
The Company’s Employee Stock Purchase Plan (the “ESPP”) provides, among other things, that the number of shares of Common Stock reserved for issuance under the ESPP will be increased on January 1 of each year, commencing on January 1, 2022 and ending on (and including) January 1, 2031 in an amount equal to the least of: (i) 1% of the total number of shares of Common Stock outstanding as of December 31 of the immediately preceding calendar year, or (ii) 200,000 shares of Common Stock; provided, however, that the Board may determine that any annual increase shall be for a number of shares of Common Stock that is less than the number of shares of Common Stock determined by the application of clauses (i) and (ii).
On June 24, 2021, the Company filed a registration statement on Form S-8 (file no. 333-257359, the “Initial Registration Statement”) with the Securities and Exchange Commission (the “Commission”) to register shares of Common Stock for issuance under the 2021 Plan, the ESPP, the Company’s 2019 Equity Incentive Plan and the Company’s 2010 Stock Incentive Plan. Pursuant to General Instruction E to Form S-8, the contents of the Initial Registration Statement are incorporated herein by reference, except for Part II, Item 8.
The Company has filed this registration statement on Form S-8 to register: (a) 1,200,000 additional shares of Common Stock not previously registered under the 2021 Plan, 600,000 of which became available for issuance under the 2021 Plan on January 1, 2023, and 600,000 of which became available for issuance under the 2021 Plan on January 1, 2022, and (b) 400,000 additional shares of Common Stock not previously registered under the ESPP, 200,000 of which became available for issuance under the ESPP on January 1, 2023, and 200,000 of which became available for issuance under the ESPP on January 1, 2022.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. | Exhibits. |
+ Filed herewith
1
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Minneapolis, State of Minnesota, on January 12, 2023.
MIROMATRIX MEDICAL INC. | ||
By: | /s/ Jeffrey Ross | |
Name: Jeffrey Ross | ||
Title: Chief Executive Officer and Director |
Each person whose signature appears below hereby constitutes and appoints Jeffrey Ross and James Douglas, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign the Registration Statement filed herewith and any and all amendments to said Registration Statement (including post-effective amendments), and file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on January 12, 2023:
Signature | Title | |
/s/ Jeffrey Ross | Chief Executive Officer and Director | |
Jeffrey Ross | (principal executive officer) | |
/s/ James Douglas | Chief Financial Officer | |
James Douglas | (principal financial and accounting officer)
| |
/s/ Paul Buckman | Director | |
Paul Buckman | ||
/s/ William Burke | Director | |
William Burke | ||
/s/ John Erb | Director | |
John Erb | ||
/s/ Lisa Wipperman Heine | Director | |
Lisa Wipperman Heine | ||
/s/ Peter Maag | Director | |
Peter Maag | ||
2